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Abstract
Embolism of cardiac origin accounts for around 15–30% of ischaemic strokes. It is worth noting that stroke from a car-
diac source carries a poorer outcome compared with other sources, having a 50% mortality at three years. Diagnosis of 
the cardioembolic source of stroke is frequently uncertain and relies on the identification of the potential cardiac source 
of embolism in the absence of significant autochthone cerebrovascular occlusive disease. Early diagnosis and appro-
priate treatment are mandatory to prevent the recurrent events that can lead to greater disability and the increased 
healthcare cost. Since cardioembolic stroke is not a single disease entity, its diagnosis requires initial clinical suspicion 
and a comprehensive evaluation, including electrocardiography, echocardiography, brain imaging, and cardiac moni-
toring. There are characteristic features suggestive of cardioembolic stroke, which help the clinicians to choose a right 
direction of diagnosis. The primary role of echocardiography is to establish the existence of the source of embolism, 
determine the likelihood that such a source is a plausible cause of stroke or systemic embolism, and guide the therapy 
in an individual patient. There is still a need for further studies assessing the optimal diagnostic methods of potential 
cardiac sources of embolism and establishment of the rules of the optimal medical prevention (antiplatelet therapy 
versus oral anticoagulation) and interventional procedures to reduce the incidence of ischaemic strokes.
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substrate can lead to atrial thromboembolism even in 
the absence of atrial fibrillation. Such an atrial cardio-
myopathy may explain many cases of embolic stroke of 
undetermined source, and oral anticoagulant drugs may 
prove to reduce the stroke risk from atrial cardiomyopathy 
given its parallels to atrial fibrillation. Non-vitamin K an-
tagonist oral anticoagulant drugs have recently expanded 
therapeutic options for preventing cardioembolic stroke 
and are currently being tested for stroke prevention in 
patients with embolic stroke of undetermined source. Also 
increasing appreciation of thrombogenic atrial substrate 
and the common coexistence of cardiac and extracardiac 
stroke risk factors suggest benefits from global vascular 
risk factor management in addition to anticoagulation. 
Finally, improved imaging of ventricular thrombus plus the 
availability of non-vitamin K antagonist oral anticoagulant 
drugs may lead to better prevention of stroke from acute 
myocardial infarction and heart failure [7].
Clinical and imaging features  
suggestive of cardioembolic stroke
The evaluation of suspected cardiac source of embolism 
requires rapid diagnostic efforts, which should include de-
tailed history, comprehensive physical examination, blood 
workup, and imaging of the heart and the organs damaged 
by the embolus. In many patients medical history, risk factor 
profile, physical exploration, and basic explorations (ECG 
and thorax X-ray) may already indicate or suggest some 
specific causes, such as the presence of carotid bruits 
originated by a carotid stenosis, rheumatic or prosthetic 
valve disease and atrial fibrillation. If no aetiology is found, 
the next step is usually directed towards identifying the 
arterial causes of embolism using ultrasound techniques, 
transcranial Doppler (TCD) and cervical arteries Doppler 
(CD), colour coded transcranial or cervical arteries duplex 
(transcranial colour coded Doppler [TCCD], arteries colour 
Doppler CCD) or angiography, usually magnetic resonance 
imaging (MRI) or computed tomography (CT) based, of the 
intracranial and cervical vessels.
Echocardiography should be the primary form of car-
diac imaging, supplemented by the chest X-ray, computed 
tomography, magnetic resonance imaging, and nuclear 
imaging when necessary. Computed tomography or MRI, 
as well as angiography, may be indispensable in the evalu-
ation of organs and tissues affected by cardiac sources of 
embolism. Cardiac emboli often occlude middle — large 
size arteries and multiple vascular territories [8].
Diagnosis of the cardioembolic source of stroke is 
frequently uncertain and relies on the identification of 
thepotential cardiac source of embolism in the absence 
of significant autochthone cerebrovascular occlusive 
disease [9]. Cardiac emboli can travel along to the intra-
cranial vessels and due to their variable size cause either 
Introduction
Stroke is a major public health issue. It is typically charac-
terised as a neurological deficit attributed to an acute focal 
injury of the central nervous system by a vascular cause, 
including cerebral infarction, intracerebral haemorrhage, 
and subarachnoid haemorrhage (SAH). Stroke is becoming 
a common disease worldwide, and has an increased rate 
of recurrence yearly after a transient ischaemic attack (TIA) 
or stroke [1]. Ischaemic stroke is a heterogeneous disease 
with different mechanisms and aetiologies and specific 
treatments. Identification of the right cause is essential in 
order to prepare an adequate preventive strategy [1]. A sub-
stantial proportion of stroke risk remains unexplained [2].
Using the Trial of Org 10172 in Acute Stroke Treatment 
(TOAST) criteria, ischaemic strokes may be further subdi-
vided into the following types:
 — thrombosis or embolism associated with large vessel 
atherosclerosis;
 — embolism of cardiac origin (cardioembolic stroke);
 — small blood vessel occlusion (lacunar stroke);
 — other determined cause;
 — undetermined (cryptogenic) cause (no cause identified, 
more than one cause, or incomplete investigation) [3].
The aetiological diagnosis of stroke in adults has 
changed over time as a result of improvements in the 
diagnostic workup.
While cryptogenic stroke was the most frequent diagno-
sis in the past, today specific causes (non-atherosclerotic 
vasculopathy, large-artery atherosclerosis, cardioembolism 
and haematological disorder) are identified in the majority 
of patients [4].
Early diagnosis and treatment of stroke improves the 
patient outcomes, and knowledge of the cause of the initial 
event is crucial to identificate the appropriate therapy to 
maximally reduce the risk of recurrence. Cardioembolic 
stroke carries a higher risk of death, recurrent stroke, and 
hospital readmission as well as higher risk of severe disa-
bility compared with other stroke subtypes. Its frequency 
is expected to rise because of the age-related incidence of 
atrial fibrillation and an aging population. Early diagnosis 
and appropriate treatment are therefore mandatory to 
prevent the recurrent events that lead to greater disability 
and increased healthcare cost.
Since cardioembolic stroke is not a single disease 
entity, its diagnosis requires initial clinical suspicion and 
a comprehensive evaluation, including electrocardiogra-
phy (ECG), echocardiography, brain imaging, and cardiac 
monitoring [5, 6].
Moreover, recent clinical trials have indicated that 
embolic stroke of undetermined source may often stem 
from subclinical atrial fibrillation, which can be diagnosed 
with prolonged heart rhythm monitoring. What is more, 
emerging evidence indicates that thrombogenic atrial 
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massive infarcts by occlusion of proximal arteries, small 
superficial infarcts in distal arterial territories, single large 
deep infarcts or multiple infarcts in different arterial terri-
tories [9]. Clinical presentation is characterised by sudden 
neurological deficits maximal at onset due to abrupt inter-
ruption of blood flow. While a stuttering course has usually 
been attributed to atherothrombotic stroke, cardioembolic 
strokes can have a progressive course in at least one-fifth 
of cases, given that emboli can recanalyse, move and frag-
ment after the initial impaction. Non-cardioembolic strokes 
can appear with sudden deficits in two-fifths of cases [9]. 
Rapid regression of symptoms (the spectacular shrinking 
syndrome) reflecting early recanalisation has also been 
related to cardioembolic stroke [9]. Neurological deficits 
and syndromes may indicate embolic mechanisms, but all 
have suboptimal discriminatory capacity [9]. Some neu-
rological syndromes such as Wernicke’s aphasia, global 
aphasia without hemiparesis, Wallenberg’s syndrome, 
cerebellar infarcts, top-of-the basilar artery syndrome have 
been commonly associated with cardiac embolism [9]. Also 
visual-field abnormalities and neglect are clinical deficits 
more frequent in cardioembolic stroke [9]. Ultrasound 
exposure could non-invasively enhance the clot lysis of 
tissue plasminogen activator (t-PA) with the presence of 
microbubbles (MBs). A variety of sonography systems are 
available in the market, and whether sonothrombolysis is 
only successful using specific devices is unknown [10].
Commercially available products containing microbub-
bles to enhance ultrasound images, termed “ultrasound 
contrast agents” (UCA) are indicated for use with trans-
thoracic echocardiography to improve cardiac structure 
and function assessment, but can also be used with 
transoesophageal echocardiography (TEE). The primary 
mechanism for UCA relies on the difference in density 
and compressibility between the microbubbles and the 
surrounding fluid and solid interfaces thus creating an 
efficient reflector of ultrasound and enhancing blood echo-
genicity [11]. The acoustic power (mechanical index) of the 
transmitted ultrasound beam plays a major role affecting 
the UCA oscillation [11]. These improvements in contrast 
specific imaging presets enable excellent visualisation of 
UCA within cardiac chambers and myocardial microvascu-
lature, as well as Doppler enhancement [11]. Neuroima-
ging of cardioembolic stroke is typically performed acutely 
via non-contrast head CT for patients presenting to the 
emergency room. However, in case of patients who present 
with subacute to chronic stroke symptoms or TIA, or when 
CT is non-diagnostic, MRI is often used.
Magnetic resonance imaging has demonstrated to 
be clearly superior to CT in identifying ischaemic lesions 
not visible on CT and has the capacity to detect cerebral 
ischaemia within minutes of onset by diffusion-weighted 
sequences (DWI). Magnetic resonance imaging is supe-
rior to CT in detecting cortical involvement and multiple 
ischaemic lesions correlating with cardioembolic stroke. 
The presence of the hyperdense cerebral artery sign on 
non-contrast CT scanning, or the corresponding hyper-
intense artery sign on MRI, originated by an occluding 
thrombus, suggests the diagnosis of an embolic arterial 
occlusion that may be of cardiac origin if no arterial pa-
thology is detected [8].
In the absence of local arterial disease, more distant 
sources of potential embolism are sought. In cardiac embo-
lism, the pattern of infarct is territorial in type and distribu-
tion. Multiplicity of lesions involving both the anterior and 
posterior circulation and/or both hemispheres particularly 
if separated by time (infarcts of different age), more than 
one infarct within a territorial distribution, or if there are 
concomitant signs of systemic thrombo-embolism (such as 
splenic or renal infarcts, or peripheral limb ischaemia), is 
highly suggestive of cardiogenic embolism [12].
In comparison, small deep penetrator infarcts of the 
lenticulostriate or brainstem (< 1 cm in size) are typically 
not cardioembolic in origin and most likely relate to small 
vessel (≤ 100 microns in diameter) disease processes, 
such as hypertension or diabetes. But there is also a spe-
cific type of subcortical infarct, the ‘large lenticulostriate 
infarct’, which typically indicates an embolic stroke mecha-
nism [13]. The identification of cortical involvement is 
characteristic of the embolic mechanism. The reports of 
migratory cardioembolic events that occlude penetrating 
vessel ostia are reported, but their involvement is typically 
greater than 1 cm in parenchymal size. Cardioembolic 
stroke affecting the posterior circulation accounts for 
≤ 25% of posterior circulation ischaemic events in some 
registries [9, 14, 15]. In Figure 1 we present the schematic 
drawings of patterns of brain infarctions signaling different 
stroke mechanisms [13].
Bilateral thalamic strokes are rare manifestations 
of posterior circulation infarcts. Usually the aetiology is 
cardioembolic or small vessel disease combined with in-
dividual anatomical predisposition. The symptoms include 
a variety of neurological deficits depending on thalamic 
structure involvement, such as paresthesias or numbness, 
hemiparesis with increased reflexes and Babinski sign, third 
cranial nerve palsy, speech and cognition disturbance, 
memory impairment and stupor. Neuroimaging usually 
reveals ischaemic loci in adequate thalamic nuclei. Bila-
teral thalamic stroke due to artery of Percheron occlusion 
is a rare presentation of stroke, which can be overlooked 
in the routine CT scan. If diagnosed, it requires further 
evaluation for stroke risk factors, especially cardiovascular 
disorders associated with the increased embolic risk [16].
Cerebral ischaemia with haemorrhagic transformation 
has been associated to cardioembolic stroke. Haemorrhag-
ic transformation occurs in up to 71% of cardioembolic 
strokes and 91% of haemorrhagic infarcts are caused by 
a cardiac embolism. Haemorrhagic transformation has 
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been traditionally explained by recanalisation of an oc-
cluded vessel to a damaged ischaemic tissue and vessel 
walls. Recanalisation after six hours of ischaemia and the 
detection of microbleeds on gradient-echo T2-weighted 
MRI are predictors of haemorrhagic transformation [8].
The features suggestive of cardioembolic stroke are 
presented in Table 1 [13].
Methods of diagnosis of cardiac embolism 
sources
Echocardiography is being increasingly used as a screening 
test to identify the sources of cardiogenic embolism in pa-
tients with ischaemic stroke or TIA. The echocardiographic 
diagnosis of cardiac thrombi, vegetations and tumours, 
as well as the identification of predisposing conditions 
such as patent foramen ovale, aortic atherosclerosis and 
other minor causes (e.g., mitral valve prolapse, mitral and 
aortic valve calcification) have crucial clinical relevance, 
affecting the choice of surgery and/or of pharmaceutical 
therapy in the setting of patients presenting embolism. 
The echocardiographic assessment helps not only for 
the retrospective diagnosis of the sources of embolism, 
but also for the prevention of events in the asymptomatic 
patients [17].
The hierarchy of echocardiography investigations be-
gins with a standard transthoracic echocardiography study 
(TTE). If the heart is deemed structurally normal, a bubble 
contrast transthoracic study (cTTE) is performed to evalu-
ate the presence of intra-cardiac shunting. For example, 
Kolo et al. [18] recruited prospectively 126 consecutive 
stroke patients in their study. The potential cardiac source 
Figure 1A–D. Schematic drawings of patterns of brain infarctions signaling different stroke mechanisms (based on [13]): A. In cortical 
infarcts with territorial distribution, cardioembolic stroke is probable; B. The same holds true for large striatocapsular infarcts; C. This is not 
the case in lacunar infarctions by definition located subcortically; D. Low flow infarct can be located subcortical (upper panel) or cortical 
(lower panel), but their distribution is not territorial but interterritorial
Table 1. Features suggestive of cardioembolic stroke (source [13])
Clinical Sudden onset to maximal deficit
Rapid regression of symptoms
Visual field defect, neglect or aphasia
Concomitant palpitations or oppressive chest 
pain
MRI or CT Simultaneous or sequential infarcts in diffe-
rent arterial territories
Haemorrhagic transformation
Hyperdense artery sign in absence of arterial 
pathology
Ultrasound Occlusion of the carotid artery by a mobile 
thrombus
Early recanalisation of an arterial occlusion
Microembolism (HITS) in both middle cere-
bral arteries
Laboratory Elevation of troponins or cardiac enzymes
Brain natriuretic peptide
MRI — magnetic resonance imaging; CT — computed tomography; HITS — high-intensity transient 
signals
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of emboli (CSE) was identified in 23.0% of the stroke pa-
tients. Five (4.0%) patients had rheumatic valvular heart 
disease with demonstrable clots in the left atrium. On 
the other hand, four (3.2%) patients had rheumatic heart 
disease without thrombi. Two patients had biventricular 
thrombi. One of these patients had giant clots within 
the ventricles and multiple freely mobile thrombi in right 
ventricle without obvious cardiac structural defect [18]. 
Transoesophageal echocardiography is indicated where 
transthoracic imaging is poor and so non-diagnostic; 
when a cardiac lesion is identified and requires further 
detailed assessment (e.g. mitral stenosis and suitability 
for percutaneous balloon mitral valvuloplasty or a positive 
cTTE requiring further detailed anatomical assessment of 
the atrial septum for risk stratification and suitability for 
device closure) or where no cardiac source for stroke has 
been identified and specific pathologies need to be ex-
cluded. Transoesophageal echocardiography provides high 
resolution images from an almost non-invasive approach 
and has revolutionised the search for cardiac sources of 
embolism. Its good sensitivity and high specificity results 
not only from its excellent resolution, but also from its 
ability to image structures that are not seen well or not 
seen at all from the transthoracic approach, including the 
left atrial appendage, the atrial septum, and the thoracic 
aorta. Transoesophageal echocardiography has therefore 
particular strengths in elucidating potential aetiology in 
cardiac sources of embolism [19].
Figure 2 shows TEE utility in detection of patent fora-
men ovale (PFO). Also modern echocardiographic methods 
could be useful in detection and prediction of potential 
reasons of ischaemic stroke. Olsen et al. [20] aimed to 
evaluate whether speckle tracking echocardiography 
improves the risk stratification for atrial fibrillation in 
these patients. The study comprised of 373 patients with 
ST-segment elevation myocardial infarction (STEMI), trea-
ted with primary percutaneous coronary intervention. The 
endpoint was a composite of new-onset atrial fibrillation 
and ischaemic stroke. After a median follow-up time of 
5.5 years, patients who reached the endpoint had signi-
ficantly reduced systolic function by the left ventricular 
ejection fraction (LVEF) (43% vs 46%, p = 0.042) and 
global longitudinal strain (10.9% vs 12.6%, p = 0.004), 
both being univariable predictors. However, only global 
longitudinal strain remained a significantly independent 
predictor (hazard ratio [HR] 1.12, 95% confidence inter-
val [CI] 1.00; 1.25, p  =  0.042, per 1% decrease) after 
multivariable adjustment for baseline predictors (age, 
sex, diabetes, hypertension, diastolic dysfunction, and 
LVEF) [20].
A thrombus located in the left atrium (LA) or, more 
likely, the LA appendage (LAA) is the most prevalent 
source of cardioembolic events and is typically associated 
with atrial fibrillation (AF). Thromboembolic risk is similar 
between paroxysmal and persistent AF, but is strongly 
determined by associated cardiovascular risk factors. The 
severity and duration of these risk factors influence the 
extent of LA enlargement and consequently the likelihood 
of AF-associated thrombus formation. The development of 
real-time three-dimensional echocardiography (RT3DE) 
has enhanced our ability to interrogate the LAA, providing 
the perspective relative to LAA anatomy as well as to 
discriminatebetween the real and artifactual mass within 
the cavity. Furthermore, its recent study demonstrated 
that RT3DE is accurate in determining LA volume, com-
pared with two-dimensional TTE [21]. Cardiac magnetic 
resonance (CMR) imaging, the current gold standard, may 
have advantages over TEE [17].
Zahuranec et al. [22] performed a prospective pilot 
study comparing CMR to TEE after stroke to assist in 
planning future definitive studies. Individuals with non-la-
cunar stroke within 90 days of undergoing clinical TEE 
were prospectively identified and underwent a 1.5 Tesla 
research CMR scan. The exclusion criteria included 
> 50% relevant cervical vessel stenosis and inability to 
undergo non-sedated CMR. A descriptive comparison of 
cardioembolic source (intracardiac thrombus/mass, aortic 
atheroma ≥ 4 mm, or PFO) by study type was performed. 
No patient had intracardiac thrombus or mass detected on 
either study. Aortic atheroma ≥ 4 mm thick was identified 
by TEE in one patient. CMR identified aortic atheroma 
as < 4 mm in this patient (3 mm on CMR compared with 
5 mm on TEE). Patent foramen ovale was identified in six 
of 20 patients on TEE; CMR found only one of these. In this 
pilot study, TEE identified more potential cardioembolic 
sources than CMR imaging. Future studies comparing 
TEE and CMR after stroke should determine whether TEE, 
CMR, or both can best elucidate potential cardioembolic 
sources [22].
Figure 2. Transoesophageal echocardiography in detection of pa-
tent foramen ovale
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From a therapeutic viewpoint, it is important to differen-
tiate the underlying causes of embolism in patients with 
cryptogenic stroke, such as aortic arch atheroma (AAA), 
PFO, and paroxysmal atrial fibrillation (PAF). Ryoo et al. [23] 
investigated the clinical and radiological characteristics of 
these three common causes of cryptogenic embolism to 
develop models for decision making in aetiologic workups. 
All the patients underwent ECG and brain magnetic reso-
nance imaging and magnetic resonance angiography in the 
emergency room. Patients who had a determined cause of 
stroke before the admission were excluded from the study, 
based on the Stop Stroke Study Trial of Org 10172 in Acute 
Stroke Treatment (SSS–TOAST).
Aortic arch atheroma was considered as a cause 
of stroke if vulnerable AAA was observed on the TEE or 
MDCT. Vulnerable AAA was defined as aortic plaques in 
the ascending aorta or proximal arch that met ≥ 1 of the 
following criteria: 1) ≥ 4 mm of intima-media thickness 
on TEE or ≥ 6 mm of thickness adjacent to the aortic wall 
on MDCT or 2) ulcerated plaque or 3) mobile plaque on 
TEE or soft plaque on MDCT [23]. Patent foramen ovale 
was deemed present when one of the following criteria 
was observed: 1) the passage of > 3 microbubbles to the 
left atrium within three cardiac cycles after a complete 
pacification of the right atrium on the TEE, 2) microembolic 
signals within 40 seconds after the injection of agitated 
saline with microbubbles on the TCD, or 3) a distinct flap 
in the left atrium at the expected location of the septum 
primum or a continuous column of contrast material con-
necting both atria or jet of contrast material into the right 
atrium on the MDCT. Patients in the PAF group were those 
who had no history or ECG findings of atrial fibrillation at 
admission, but PAF was diagnosed using repetitive ECGs 
or 72–hour cardiac telemetry. If patients had PAF plus 
PFO or AAA, they were classified as belonging to the PAF 
group, because the current evidence–based classification 
system classifies PAF as a high–risk embolic source and 
PFO and AAA as low or uncertain sources of embolism [24].
The authors of the study based on observed distinct 
clinical and radiological characteristics for AAA, PFO, and 
PAF patients developed an equation to predict the most 
probable aetiology underlying cryptogenic embolisms. 
Their data indicate that patients with embolic stroke of 
undetermined source showed distinct clinical and radio-
logical features depending on the underlying stroke cause. 
Specific diagnostic tests for aortocardiac sources could be 
guided by such features. Continuous efforts are needed 
to refine the approach to working up cases of suspected 
embolic stroke of undetermined source, incorporating 
other biomarkers, such as B-type natriuretic peptide or 
genetic risk factors [23].
Iwasaki et al. [25] analysed the potential utility of 
multidetector computed tomography (MDCT) to identify 
both cardiac embolic sources and coronary artery disease 
(CAD) in embolic-stroke patients. They performed MDCT 
for 184 patients with embolic stroke and investigated 
the prevalence of the potential source of the embolism. 
Overall, 64 potential embolic sources were detected in 
59 patients (32.1%). Left atrial appendage thrombus, left 
ventricular thrombus and aortic atheroma were detected 
in 3.3, 0.5 and 15.8% of patients, respectively. Circulatory 
stasis and patent foramen ovale were detected in 8.7 and 
6.5%, respectively. Their results suggest that MDCT has 
a potential to identify cardiac embolic sources in patients 
with embolic stroke, but without known CAD [25].
Lee et al. [26] performed a study, which purpose was 
to investigate cardiac computed tomographic (CT) findings 
predictive of recurrent stroke in patients with ischaemic 
stroke and determine the incremental risk stratification 
benefit of cardiac CT findings compared with TEE findings 
in patients with ischaemic stroke. Transoesophageal 
echocardiography and cardiac CT images were assessed 
in 374 patients with ischaemic stroke for cardioembolic 
sources, including thrombus, tumour, spontaneous echo 
contrast, valvular vegetation, atrial septal aneurysm, patent 
foramen ovale, and aortic plaque. The primary end point 
was stroke recurrence. During a median follow-up period of 
433 days, there were a total of 28 recurrent stroke events. 
The TEE parameter of plaque complexity (HR, 13.512; 
95% CI: 3.668, 49.778; p < 0.001) and CT parameter of 
plaque complexity (HR, 32.538; 95% CI: 7.544, 140.347; 
p < 0.001) were predictors of the recurrent stroke. The 
time-dependent receiver operating characteristic curve 
analysis demonstrated no significant differences in predic-
tion of recurrent stroke between TEE and CT parameters 
(integrated area under the receiver operating characteristic 
curve, 0.812 vs 0.840, respectively) [26].
Summary
Strokes due to cardiac embolism are generally associa-
ted with poor prognosis. Cardioembolic stroke has been 
associa ted with short and long-term recurrence, higher 
in-hospital mortality and a higher index of fatal recurrence 
versus other causes of stroke. Identification of the specific 
cause is crucial in order to choose the most optimal pre-
ventive strategy and these vary for the different subtypes 
of ischaemic stroke [27]. There are characteristic features 
suggestive of cardioembolic stroke which help clinicians 
to choose a right direction of diagnosis. About 80% of 
ischaemic strokes occur in persons without AF, and it is 
therefore important to develop a path to examine the 
optimal prevention of stroke when there is no obvious AF 
[28, 29]. The cryptogenic strokes are being recognised as 
sharing many characteristics with cardioembolic strokes 
[30]. Currently available data do not provide definitive 
evidence on the comparative benefits of OAC vs. APT in 
patients with cryptogenic stroke [31]. There are ongoing 
27www.journals.viamedica.pl/folia_cardiologica
Paulina Gąsiorek et al., Stroke as a result of cardioembolism
studies assessing advantages and disadvantages of these 
two kinds of therapies. There is also a lack of antitrom-
bothic treatment scheme in the time between stroke and 
diagnosis of potential sources of thromboembolism in 
cryptogenic stroke.
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Streszczenie
Zator pochodzenia sercowego stanowi przyczynę 15–30% udarów niedokrwiennych. Warto zauważyć, że udar kardio-
genny charakteryzuje się gorszym rokowaniem w porównaniu z udarami o innej etiologii i wiąże się z około 50-procen-
tową śmiertelnością w czasie 3 lat. Ustalenie przyczyny udaru kardiogennego bywa nierzadko trudne i opiera się na 
identyfikacji potencjalnych przyczyn zatoru pochodzenia sercowego przy braku istotnych pierwotnych schorzeń sercowo-
-mózgowych. Wczesne rozpoznanie i odpowiednie leczenie są niezbędne, by nie dopuścić do nawrotu incydentu udaro-
wego, który prowadzi do niepełnosprawności oraz wiąże się ze wzrostem kosztów ochrony zdrowia. Udar kardiogenny ma 
charakterystyczne cechy zarówno w obrazie klinicznym, jak i w badaniach dodatkowych, których rozpoznanie pozwala 
lekarzowi wybrać właściwy kierunek prowadzonej diagnostyki. Ponieważ udar kardiogenny nie jest odrębną jednostką 
chorobową, to jego rozpoznanie wymaga od samego początku odpowiedniego podejścia klinicznego oraz kompleksowej 
diagnostyki, włączając elektrokardiografię, echokardiografię, obrazowanie mózgu i monitorowanie pracy serca. Podsta-
wowa rola echokardiografii sprowadza się do ustalenia źródła zatorowości, oceny prawdopodobieństwa, z jakim stanowi 
ono rzeczywistą przyczynę udaru lub zatorowości obwodowej, a także pomaga w określeniu indywidualnej dla każdego 
pacjenta terapii. Wciąż istnieje potrzeba opracowania optymalnych metod diagnostyki potencjalnych kardiogennych 
przyczyn zatorowości oraz określenia optymalnych zasad prewencji (leczenie przeciwpłytkowe lub doustna antykoagula-
cja), a także procedur interwencyjnych, aby zmniejszyć częstotliwość udarów niedokrwiennych.
Słowa kluczowe: udar niedokrwienny, echokardiografia, zator, obrazowanie mózgu
Folia Cardiologica 2018; 13, 1: 21–28
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